INSMED INC Increase (Decrease) in Deferred Revenue
INSMED INC (INSM) reported Increase (Decrease) in Deferred Revenue of $0 for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-18.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2014-03-06
- INSMED INC increase (decrease) in deferred revenue for the quarter ending 2012-12-31 was $0.00.
- INSMED INC increase (decrease) in deferred revenue for the quarter ending 2012-09-30 was $0.00, a 100.00% decline year-over-year.
- INSMED INC increase (decrease) in deferred revenue for the quarter ending 2012-06-30 was $0.00.
- INSMED INC increase (decrease) in deferred revenue for the quarter ending 2012-03-31 was $0.00.
- INSMED INC increase (decrease) in deferred revenue for fiscal 2012 was $0.00.
- INSMED INC increase (decrease) in deferred revenue for fiscal 2011 was -$402.00K, a 10150.00% decline from fiscal 2010.
- INSMED INC increase (decrease) in deferred revenue for fiscal 2010 was $4.00K, a 95.83% decline from fiscal 2009.
- INSMED INC increase (decrease) in deferred revenue for fiscal 2009 was $96.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $0.00 derived: sum of 2 quarters · filed 2013-03-18 | $0.00 derived: sum of 3 quarters · filed 2013-03-18 | $0.00 10-K · filed 2013-03-18 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $0.00 derived: sum of 2 quarters · filed 2012-11-07 | $0.00 10-Q · filed 2012-11-07 | -$421.00K derived: sum of 4 quarters · filed 2014-03-06 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $0.00 10-Q · filed 2012-08-07 | -$421.00K derived: sum of 3 quarters · filed 2014-03-06 | -$195.00K derived: sum of 4 quarters · filed 2014-03-06 |
| 2012-03-31 | $0.00 10-Q · filed 2012-05-08 | -$421.00K derived: sum of 2 quarters · filed 2014-03-06 | -$195.00K derived: sum of 3 quarters · filed 2014-03-06 | -$244.00K derived: sum of 4 quarters · filed 2014-03-06 |
| 2011-12-31 | -$421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-06 | -$195.00K derived: sum of 2 quarters · filed 2014-03-06 | -$244.00K derived: sum of 3 quarters · filed 2014-03-06 | -$402.00K 10-K · filed 2014-03-06 |
| 2011-09-30 | $226.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $177.00K derived: sum of 2 quarters · filed 2012-11-07 | $19.00K 10-Q · filed 2012-11-07 | $323.00K derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | -$49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | -$207.00K 10-Q · filed 2012-08-07 | $97.00K derived: sum of 3 quarters · filed 2013-03-18 | -$243.00K derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | -$158.00K 10-Q · filed 2012-05-08 | $146.00K derived: sum of 2 quarters · filed 2013-03-18 | -$194.00K derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | $304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | -$36.00K derived: sum of 2 quarters · filed 2013-03-18 | $4.00K 10-K · filed 2013-03-18 | |
| 2010-09-30 | -$340.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-09 | -$300.00K 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | $40.00K 10-Q/A · filed 2011-08-08 | |||
| 2009-12-31 | $96.00K 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |